Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     
  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     
  • Bitcoin GBP

    48,746.74
    -1,372.55 (-2.74%)
     
  • CMC Crypto 200

    1,261.74
    -96.27 (-7.09%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

Company News for Apr 17, 2020

  • Shares of Taiwan Semiconductor Manufacturing Company Limited TSM rose 5.5% after the company reported first-quarter earnings of 75 cents per share, surpassing the Zacks Consensus Estimate of 66 cents.

  • Shares of The Bank of New York Mellon Corporation BK rose 4.4% after the company reported first-quarter 2020 earnings per share of $1.05 that surpassed the Zacks Consensus Estimate of 90 cents.

  • Shares of The Lovesac Company LOVE jumped 27.3% after the company reported fourth quarter of fiscal 2020 of $0.37 per share, beating the Zacks Consensus Estimate of $0.31.

  • Shares of Vanda Pharmaceuticals Inc. VNDA rose 6.9% after the company announced the enrollment of the first patient in the company's ODYSSEY trial.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
The Bank of New York Mellon Corporation (BK) : Free Stock Analysis Report
 
Taiwan Semiconductor Manufacturing Company Ltd. (TSM) : Free Stock Analysis Report
 
Vanda Pharmaceuticals Inc. (VNDA) : Free Stock Analysis Report
 
The Lovesac Company (LOVE) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research